<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Veracyte Inc — News on 6ix</title>
<link>https://6ix.com/company/veracyte-inc</link>
<description>Latest news and press releases for Veracyte Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Tue, 28 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/veracyte-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835d1f178dffbe2df11fecb.webp</url>
<title>Veracyte Inc</title>
<link>https://6ix.com/company/veracyte-inc</link>
</image>
<item>
<title>Veracyte Announces New Data at AUA 2026 Highlighting the Power of the Decipher Portfolio to Advance Personalized Care in Urologic Cancers</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-announces-new-data-at-aua-2026-highlighting-the-power-of-the-decipher-portfolio-to-advance-personalized-care-in-urologic-cancers</guid>
<pubDate>Tue, 28 Apr 2026 04:00:00 GMT</pubDate>
<description>Studies demonstrate clinical utility of Decipher Bladder molecular subtyping in bladder cancer and the expanding impact of Decipher Prostate in studies using</description>
</item>
<item>
<title>Veracyte to Release First Quarter 2026 Financial Results on May 5, 2026</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-to-release-first-quarter-2026-financial-results-on-may-5-2026</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-to-release-first-quarter-2026-financial-results-on-may-5-2026</guid>
<pubDate>Tue, 14 Apr 2026 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., April 14, 2026--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the first quarter 2026 after the close of market on Tuesday, May 5, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.</description>
</item>
<item>
<title>Veracyte Names Kevin Haas as Chief Development and Technology Officer</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-names-kevin-haas-as-chief-development-and-technology-officer</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-names-kevin-haas-as-chief-development-and-technology-officer</guid>
<pubDate>Mon, 16 Mar 2026 20:15:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., March 16, 2026--Veracyte Names Kevin Haas as Chief Development and Technology Officer</description>
</item>
<item>
<title>Veracyte Announces Fourth Quarter and Full Year 2025 Financial Results</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-announces-fourth-quarter-and-full-year-2025-financial-results</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-announces-fourth-quarter-and-full-year-2025-financial-results</guid>
<pubDate>Wed, 25 Feb 2026 05:00:00 GMT</pubDate>
<description>Grew fourth quarter total revenue to $140.6 million, an increase of 19% Grew fourth quarter testing revenue to $135.8 million, an increase of 21% Conference</description>
</item>
<item>
<title>Veracyte to Highlight Extensive Decipher® Data at 2026 ASCO GU Symposium</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-to-highlight-extensive-decipherr-data-at-2026-asco-gu-symposium</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-to-highlight-extensive-decipherr-data-at-2026-asco-gu-symposium</guid>
<pubDate>Tue, 24 Feb 2026 05:00:00 GMT</pubDate>
<description>More than 15 abstracts showcase how the Veracyte Diagnostics Platform is advancing urologic cancer care with decisions guided by Decipher Prostate and</description>
</item>
<item>
<title>Veracyte to Release Fourth Quarter and Full-Year 2025 Financial Results on February 25, 2026</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-release-fourth-quarter-full-221500413</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-release-fourth-quarter-full-221500413</guid>
<pubDate>Wed, 04 Feb 2026 22:15:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., February 04, 2026--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release financial results for the fourth quarter and full-year 2025 after the close of market on Wednesday, February 25, 2026. Company management will host a conference call and webcast to discuss financial results and provide a general business update at 4:30 p.m. Eastern Time on the same day.</description>
</item>
<item>
<title>Veracyte Announces Preliminary Fourth Quarter and Full-Year 2025 Results</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-announces-preliminary-fourth-quarter-213000873</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-announces-preliminary-fourth-quarter-213000873</guid>
<pubDate>Sun, 11 Jan 2026 21:30:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., January 11, 2026--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced preliminary, unaudited financial results for the fourth quarter and full year ended December 31, 2025.</description>
</item>
<item>
<title>Veracyte to Participate in the 44th Annual J.P. Morgan Healthcare Conference</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-participate-44th-annual-jp-morgan-healthcare-conference-2025-12-29</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-participate-44th-annual-jp-morgan-healthcare-conference-2025-12-29</guid>
<pubDate>Mon, 29 Dec 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that management will</description>
</item>
<item>
<title>Veracyte to Participate in Upcoming Investor Conferences</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-participate-upcoming-investor-conferences-2025-11-06</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-participate-upcoming-investor-conferences-2025-11-06</guid>
<pubDate>Thu, 06 Nov 2025 05:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) a leading cancer diagnostics company, announced today it will participate in the</description>
</item>
<item>
<title>Veracyte Announces Third Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-announces-third-quarter-2025-financial-results-2025-11-04</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-announces-third-quarter-2025-financial-results-2025-11-04</guid>
<pubDate>Tue, 04 Nov 2025 05:00:00 GMT</pubDate>
<description>Grew total revenue to $131.9 million and testing revenue to $127.8 million, representing increases of 14% and 17% year-over-year, respectively Conference</description>
</item>
<item>
<title>Veracyte Announces First Publications Using Afirma GRID Research Tool To Help Usher in Next Generation of Thyroid Nodule Testing</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-announces-first-publications-using-afirma-grid-research-tool-help-usher-next</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-announces-first-publications-using-afirma-grid-research-tool-help-usher-next</guid>
<pubDate>Mon, 03 Nov 2025 05:00:00 GMT</pubDate>
<description>Landmark studies leverage Afirma GRID whole transcriptome-derived data to identify molecular classifiers and signatures differentiating thyroid cancer risk</description>
</item>
<item>
<title>Veracyte to Release Third Quarter 2025 Financial Results on November 4, 2025</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-release-third-quarter-2025-financial-results-november-4-2025-2025-10-15</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-release-third-quarter-2025-financial-results-november-4-2025-2025-10-15</guid>
<pubDate>Wed, 15 Oct 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, announced today that it will release</description>
</item>
<item>
<title>Veracyte Announces that Decipher-Enabled Biomarker Predicts Hormone Therapy Benefit in Men with Recurrent Prostate Cancer</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-announces-decipher-enabled-biomarker-predicts-hormone-therapy-benefit-men</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-announces-decipher-enabled-biomarker-predicts-hormone-therapy-benefit-men</guid>
<pubDate>Sun, 28 Sep 2025 04:00:00 GMT</pubDate>
<description>Findings from the first prospective validation trial for biomarker presented at ASTRO 2025 SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc.</description>
</item>
<item>
<title>Veracyte Announces First Prospective Validation Data for Biomarker Predicting Hormone Therapy Benefit in Men with Recurrent Prostate Cancer Will Be Presented at ASTRO 2025</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-announces-first-prospective-validation-data-biomarker-predicting-hormone</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-announces-first-prospective-validation-data-biomarker-predicting-hormone</guid>
<pubDate>Wed, 24 Sep 2025 04:00:00 GMT</pubDate>
<description>Findings are among nine Decipher-focused abstracts being presented at annual conference SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc.</description>
</item>
<item>
<title>Veracyte Announces That More Than 10 Afirma-Focused Studies Will Be Presented at the 2025 American Thyroid Association Annual Meeting</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-announces-more-10-afirma-focused-studies-will-be-presented-2025-american</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-announces-more-10-afirma-focused-studies-will-be-presented-2025-american</guid>
<pubDate>Tue, 09 Sep 2025 04:00:00 GMT</pubDate>
<description>Studies leverage company’s Afirma Genomic Resource for Intelligent Discovery (GRID), world’s largest molecular database for thyroid nodules SOUTH SAN</description>
</item>
<item>
<title>Veracyte to Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-participate-morgan-stanley-23rd-annual-global-healthcare-conference-2025-08</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-participate-morgan-stanley-23rd-annual-global-healthcare-conference-2025-08</guid>
<pubDate>Fri, 29 Aug 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT) announced today that management will participate in a fireside chat at the</description>
</item>
<item>
<title>Veracyte Announces New Study Published in Cell Shows that Decipher Prostate Test Predicts Chemotherapy Benefit in Patients with Metastatic Prostate Cancer</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-announces-new-study-published-cell-shows-decipher-prostate-test-predicts</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-announces-new-study-published-cell-shows-decipher-prostate-test-predicts</guid>
<pubDate>Wed, 27 Aug 2025 04:00:00 GMT</pubDate>
<description>Findings are from the multicenter, prospective, Phase 3 STAMPEDE trial SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a</description>
</item>
<item>
<title>Veracyte Completes NIGHTINGALE Clinical Utility Trial Enrollment for Percepta Nasal Swab Lung Cancer Test</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-completes-nightingale-clinical-utility-trial-enrollment-percepta-nasal-swab</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-completes-nightingale-clinical-utility-trial-enrollment-percepta-nasal-swab</guid>
<pubDate>Tue, 26 Aug 2025 04:00:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)-- Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced it has met its targeted</description>
</item>
<item>
<title>Helix and Veracyte Partner to Expand Access to Clinically Actionable Genomic Insights in Prostate Cancer Care</title>
<link>https://6ix.com/company/veracyte-inc/news/helix-and-veracyte-partner-to-expand-access-to-clinically-actionable-genomic-insights-in-prostate-cancer-care</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/helix-and-veracyte-partner-to-expand-access-to-clinically-actionable-genomic-insights-in-prostate-cancer-care</guid>
<pubDate>Thu, 07 Aug 2025 13:00:00 GMT</pubDate>
<description>Helix, a leader in precision health, today announced a partnership with leading cancer diagnostics company Veracyte that will make it easier for urologists to add comprehensive germline testing for patients with high-risk localized and metastatic prostate cancer. Through this collaboration, Helix's whole-exome based hereditary cancer test will be available alongside Veracyte's Decipher® Prostate test, enabling a more complete view of each patient's cancer biology and inherited risk.</description>
</item>
<item>
<title>Veracyte Announces Second Quarter 2025 Financial Results</title>
<link>https://6ix.com/company/veracyte-inc/news/veracyte-announces-second-quarter-2025-200500484</link>
<guid isPermaLink="true">https://6ix.com/company/veracyte-inc/news/veracyte-announces-second-quarter-2025-200500484</guid>
<pubDate>Wed, 06 Aug 2025 20:05:00 GMT</pubDate>
<description>SOUTH SAN FRANCISCO, Calif., August 06, 2025--Veracyte, Inc. (Nasdaq: VCYT), a leading cancer diagnostics company, today announced financial results for the second quarter ended June 30, 2025.</description>
</item>
</channel>
</rss>